(Sharecast News) - Norway is set to delay its decision on whether to resume Covid-19 vaccinations with the AstraZeneca jab by another three weeks, the country's Institute of Public Health (FHI) said on Friday.
The vaccine was suspended on 11 March over fears that it was causing blood clots, bleeding and low platelet counts.
"We have decided to continue the pause and make a new decision by April 15," FHI chief Camilla Stoltenberg told broadcaster NRK.
"We have started several processes to map out whether there is a causality and to have a better basis to establish the real risk and a cost-benefit analysis for different age groups. To get more knowledge, it is necessary to have more time."
Norway is among many European countries to suspend the rollout of the vaccine over safety concerns. Some have since resumed its use following positive advice from the European Medicines Agency.
Norway currently uses the Pfizer/BioNTech and Moderna jabs and will be adding that from Johnson & Johnson once supplies become available in Europe.
Astrazeneca (AZN)12 Jun 2024 20:56
AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes
(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.